ARVN Q4 2021 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+1085.9% YoY

Gross Profit

$25M94.1% margin

Operating Income

-$54M-206.8% margin

Net Income

-$53M-201.5% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

+182.8%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$38M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$800M

Stockholders' Equity

$782M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$2M	+1085.9%
Gross Profit	$25M	$2M	+1015.7%
Operating Income	-$54M	-$43M	-25.9%
Net Income	-$53M	-$42M	-27.6%